Wyden biomaterials inquiry
This article was originally published in The Gray Sheet
Executive Summary
Staffers from Rep. Ron Wyden's (D-Ore.) office request a meeting with FDA officials to discuss biomaterials availability. Wyden had written HHS Secretary Donna Shalala about potential biomaterials shortages in the spring ("The Gray Sheet" May 9, p. 25). Shalala responded that HHS shares "your desire to avoid any needless disruption to the availability of" permanent implants. Acknowledging that "shortages of biomaterials may occur" with potentially "severe" consequences, Shalala outlined "actions taken" by the department that "demonstrate a commitment to ensuring" American leadership in the area of medical technology
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.